The difficulties industry is facing with investigators.
The number of new agents being developed for the treatment of cancer has, over the past 10 years, increased dramatically which has resulted in increased interactions between the pharmaceutical industry that discover and develop most new agents and investigators in academic institutions, hospitals and office practices. This close interaction has inevitably led to a number of issues being identified on both sides and this paper will attempt to identify some of these and propose solutions.
Blackledge
George R P
GR
AstraZeneca Pharmaceuticals, Medical Oncology, Alderley House, Alderley Park, Macclesfield, Cheshire SK10 4TF, UK. george.blackledge@astrazeneca.com
D000970:Antineoplastic Agents; D001709:Biotechnology / Q000458:organization & administration*; D002986:Clinical Trials as Topic / Q000379:methods*; D015195:Drug Design; D004345:Drug Industry / Q000458:organization & administration*; D006801:Humans; D007400:Interprofessional Relations; D012108:Research Personnel
D000970:Antineoplastic Agents